archiveEli Lilly &

CANADA - 2025/04/02: In this photo illustration, the Eli Lilly and Company logo is seen displayed on ... More a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Eli Lilly’s (NYSE: LLY) first-quarter performance was mixed, with revenue meeting expectations but earnings falling short. The company reported adjusted earnings of $3.34 per share versus the projected $3.46, while revenue reached $12.7 billion, aligning with consensus estimates. Although Eli Lilly experienced lower price realization, the strong volume growth for its key drugs contributed positively...

In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. - Image: Mario Tama / Staff (Getty Images) Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular diabetes drug Ozempic. Deloitte’s annual report, Measuring the Return from Pharmaceutical Innovation, found that GLP-1 drugs could fuel significant returns on research and development investments made last year by major drugmakers. The consulting firm analyzed the...

Johnson & Johnson says it will spend $55 billion in the U.S. over the next four years, including by building three new manufacturing sites and expanding others already in its medicines and medtech network. The company announced the plan in conjunction with breaking ground on a new 500,000-square-foot biologics plant in Wilson, North Carolina. In October of last year, J&J revealed its plan to spend more than $2 billion to build the facility, which will create more than 500 jobs and will produce treatments for cancer, immunology and neuroscience disorders....